Safety Study of AMG 228 to Treat Solid Tumors
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.
Advanced Malignancy|Advanced Solid Tumors|Cancer|Oncology|Oncology Patients|Tumors|Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck|Transitional Cell Carinoma of Bladder|Colorectal Cancer
DRUG: AMG 228
Subject incidence of dose limiting toxicities (DLT), 9 months|Subject incidence of treatment-emergent adverse events, 9 months|Subject incidence of treatment-related adverse events, 9 months|Subject incidence of clinically significant changes in vital signs and physical assessments, 9 months|Subject incidence of clinically significant changes in ECGs, 9 months|Subject incidence of clinically significant changes in clinical laboratory tests, 9 months|AMG 228 maximum observed concentration (Cmax), 9 months|AMG 228 minimum observed concentration (Cmin), 9 months|AMG 228 area under the concentration-time curve (AUC), 9 months|AMG 228 half-life (t1/2), 9 months
Subject objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, 9 months|Incidence of anti-AMG 228 antibody formation, 9 months|Activation status and changes in numbers of T regulator cells (Treg), 9 months|Subject objective response per immune-related Response Criteria (irRC), 9 months|Activation status of cytotoxic T lymphocytes (CTL), 9 months|Changes in numbers of cytotoxic T lymphocytes (CTL), 9 months
The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.